Advertisement

Advertisement

MIRA Stock Latest News

Psychedelic: Clearmind initiates Phase IIa of CMND-100 trial

The FlyPsychedelic: Clearmind initiates Phase IIa of CMND-100 trial

MIRA-55 toxicology results advance non-opioid pain program

PremiumCompany Announcements

MIRA-55 toxicology results advance non-opioid pain program

3d ago

Mira Pharmaceuticals announces results from MIRA-55 studies

PremiumThe Fly

Mira Pharmaceuticals announces results from MIRA-55 studies

3d ago

Mira reports positive results in 7-day dog study for obesity candidate SKNY-1

PremiumThe Fly

Mira reports positive results in 7-day dog study for obesity candidate SKNY-1

29d ago

MIRA Reports Positive Preclinical Results for Obesity Candidate SKNY-1

PremiumCompany Announcements

MIRA Reports Positive Preclinical Results for Obesity Candidate SKNY-1

29d ago

MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice

PremiumCompany AnnouncementsMIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice

1M ago

Mira Pharmaceuticals provides update on MIRA-55, SKNY-1

The Fly

Mira Pharmaceuticals provides update on MIRA-55, SKNY-1

1M ago

MIRA Pharmaceuticals announces positive preclinical results for MIRA-55

Company Announcements

MIRA Pharmaceuticals announces positive preclinical results for MIRA-55

2M ago

Mira Pharmaceuticals reports formulation results for MIRA-55

PremiumThe Fly

Mira Pharmaceuticals reports formulation results for MIRA-55

2M ago

MIRA Reports Positive Preclinical Data for SKNY-1 Program

PremiumCompany Announcements

MIRA Reports Positive Preclinical Data for SKNY-1 Program

2M ago

Mira Pharmaceuticals reports SKNY-1 formulation results

PremiumThe Fly

Mira Pharmaceuticals reports SKNY-1 formulation results

2M ago

MIRA Unveils Differentiated Preclinical Data for Mira-55

PremiumCompany Announcements

MIRA Unveils Differentiated Preclinical Data for Mira-55

2M ago

Mira Pharmaceuticals reports preclinical pharmacology data on Mira-55

PremiumThe FlyMira Pharmaceuticals reports preclinical pharmacology data on Mira-55

2M ago

Psychedelic: Clearmind completes Part A dosing for Phase I/II CMND-100 trial

The Fly

Psychedelic: Clearmind completes Part A dosing for Phase I/II CMND-100 trial

3M ago

MIRA Advances Ketamir-2 Into FDA-Accepted Phase 2a Trial

Company Announcements

MIRA Advances Ketamir-2 Into FDA-Accepted Phase 2a Trial

3M ago

Mira Pharmaceuticals submits Phase 2a trial protocol to U.S. FDA for Ketamir-2

PremiumThe Fly

Mira Pharmaceuticals submits Phase 2a trial protocol to U.S. FDA for Ketamir-2

3M ago

Psychedelic: Optimi Health completes psilocybin export to the UK

PremiumThe Fly

Psychedelic: Optimi Health completes psilocybin export to the UK

3M ago

MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer

PremiumCompany Announcements

MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer

3M ago

Psychedelic: Enveric initiates IND-enabling genotoxicity studies of EB-003

PremiumThe Fly

Psychedelic: Enveric initiates IND-enabling genotoxicity studies of EB-003

3M ago

MIRA Pharmaceuticals Secures Unified Global Rights to Pipeline

PremiumCompany AnnouncementsMIRA Pharmaceuticals Secures Unified Global Rights to Pipeline

3M ago

Mira Pharmaceuticals secures worldwide rights to MIRA-55, SKNY-1

The Fly

Mira Pharmaceuticals secures worldwide rights to MIRA-55, SKNY-1

3M ago

Psychedelic: Optimi Health advances natural psilocybin extract

The Fly

Psychedelic: Optimi Health advances natural psilocybin extract

3M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >